Efficacy and safety of empagliflozin (SGLT2 inhibitor) in Bangladeshi patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253934Keywords:
Empagliflozin, Glycemic control, SGLT2 inhibitor, T2DMAbstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder requiring effective glycemic control to prevent complications.
Methods: This 8-month, randomized, open-label, interventional, single centered trial enrolled 86 Bangladeshi patients with poorly controlled T2DM (HbA1c ≥7.5%) on various antidiabetic regimens. Participants received Empagliflozin 10mg/25mg in addition to their ongoing therapy. Follow-ups at 6 weeks and 6 months evaluated glycemic control, lipid profile, renal parameters and adverse effects. Based on clinical response, the dosage was increased to 25 mg in selected cases. Statistical analyses included paired t-tests and Wilcoxon Signed Rank tests for normally and non-normally distributed variables.
Results: Hypertension was prevalent in 73.3% of cases, while chronic kidney disease (CKD), ischemic heart disease and dyslipidemia were observed in 12.8%, 14% and 37.2% of cases, respectively. Significant reductions in fasting blood sugar, postprandial blood sugar, systolic blood pressure (p<0.001 for all) and HbA1c (p<0.001) were observed at both 6-week and 6-month follow-ups. BMI reduction was significant at 6 months (p=0.03), while serum potassium increased significantly at both time points (p=0.02, p=0.01). Serum creatinine showed a significant decline at 6 months, while changes in LDL, triglycerides, HDL and total cholesterol were not statistically significant. Adverse effects were minimal, with 3.5% experiencing genital mycotic infections and 1.2% experiencing hypoglycemia.
Conclusions: Empagliflozin effectively improved glycemic control and systolic blood pressure reduction with minimal adverse effects in Bangladeshi T2DM patients while increasing serum potassium level.
Metrics
References
Adams FR. From association to union: Professional organization of asylum attendants, 1869-1919. British J Sociol. 1969;20(1):11-26. DOI: https://doi.org/10.2307/588996
Meyer-bahlburg H. Research priorities for gender nonconforming/transgender youth. Current Opinion in Endocrinology, Diabetes & Obesity. 2016.
Khan MAB. Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. J Epidemiol Global Health. 2020;10(1):107–11. DOI: https://doi.org/10.2991/jegh.k.191028.001
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. DOI: https://doi.org/10.1056/NEJMoa1504720
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34. DOI: https://doi.org/10.1056/NEJMoa1515920
Hossain SMF, Gulshan J, Khanam P. Type 2 diabetes in Bangladesh and associated risk factors. Int J Diabetes Dev Ctries. 2015;35(3):364–70. DOI: https://doi.org/10.1007/s13410-015-0376-2
Joysoual MR, Ara S, Haque MN, Ghosh R, Afroze T, Aufi SS. Efficacy of Empagliflozin as Add-on Therapy in Patients with Uncontrolled Type 2 Diabetes Mellitus. TAJ: J Teach Asso. 2023;36(1):89-95. DOI: https://doi.org/10.3329/taj.v36i1.68304
Saifuddin M, Paul AK, Shefin SM, Alam MJ, Selim S, Islam S, et al. Evaluation of Efficacy and Safety of Empagliflozin in Bangladeshi Patients with Type 2 Diabetes Mellitus (EFFISAEM Study). Indian J Endocrinol Metabol. 2024;28(5):500-9. DOI: https://doi.org/10.4103/ijem.ijem_189_23
Charlwood C, Chudasama J, Darling AL, Ellis HL, Whyte MB. Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis. Diabetes Res Clin Pract. 2023;196:110239. DOI: https://doi.org/10.1016/j.diabres.2023.110239
Cianciolo G, De Pascalis A, Gasperoni L, Tondolo F, Zappulo F, Capelli I. The off-target effects, electrolyte and mineral disorders of SGLT2i. Molecules. 2020;25(12):2757. DOI: https://doi.org/10.3390/molecules25122757
Hüttl M. In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia’, International J Mol Sci. 2021;22(21):5113. DOI: https://doi.org/10.3390/ijms222111513
Tikkanen, I. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420–8. DOI: https://doi.org/10.2337/dc14-1096
Downloads
Published
How to Cite
Issue
Section
